Tramosayr (Trastuzumab)TM

Trastuzumab for Injection 440 mg / 150 mg

Trastuzumab is an antineoplastic agent and is a recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2).

Indication:

It is a HER2/neu receptor antagonist indicated for:

  • The treatment of HER2-overexpressing breast cancer.
  • The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Dosage Forms and Strengths

Trastuzumab for injection 440mg

Lyophilized Powder for concentrate for solution for Intravenous Infusion.

For IV infusion after reconstitution with 20 mL Bacteriostatic Water for Injection (diluent) provided with the pack.

 

For any medical enquiry,

Contact us at: +91 9591736262 or

Email us at info@sayretherapeutics.com

MejorAsp - Sayre therapeutics